The reversal removes a significant legal barrier for Teva's breach-of-contract claim against Lilly. Monitor for discovery developments and potential settlement discussions; a favorable outcome could unlock damages from lost generic Forteo sales during the exclusivity period. The case now proceeds to merits discovery.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 14 $31.82entry
- T+1 · 4mo ago −0.82%α −1.21% · $31.56
- T+5 · 4mo ago −1.48%α −1.00% · $31.35
- T+20 · 3mo ago +14.64%α +12.15% · $36.48
- T+60 · 6w ago +23.13%α +19.50% · $39.18
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The Seventh Circuit reversed the district court's dismissal of Teva's breach-of-contract claim against Eli Lilly, holding that Teva plausibly alleged Lilly violated a 2018 settlement agreement by seeking additional regulatory exclusivity that blocked Teva's generic Forteo entry. The case is remanded for further proceedings, reviving Teva's claim that Lilly's covenants not to obstruct generic competition survived the expiration of the underlying patents.
Court Ruling Details
Key Facts
- Seventh Circuit reversed dismissal of Teva's breach-of-contract claim against Eli Lilly
- Teva alleged Lilly violated a 2018 settlement agreement by obtaining 3 years of additional regulatory exclusivity (Nov 2020–Nov 2023) that blocked Teva's generic Forteo entry
- District court had ruled the settlement agreement expired when Forteo patents expired (Aug 19, 2019); Seventh Circuit found the agreement's duration is a factual question not resolvable on the pleadings
- Teva's covenant not to sue and other provisions plausibly survived patent expiration, supporting that Lilly's non-obstruction covenant also remained in effect
- Case remanded for further proceedings on the merits
Financial Impact
Potential damages from lost generic Forteo market access during Nov 2020–Nov 2023 exclusivity period; no dollar amount stated in the opinion
Risk Factors
- Teva must still prove breach, causation, and damages on remand
- Lilly may seek interlocutory appeal or certiorari
- Litigation could extend for years with uncertain outcome
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-25219da5fd-TEVA |
Track record
61 reports on TEVA
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 14 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers